Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DKP2I0
|
|||
| Drug Name |
Encaleret
|
|||
| Synonyms |
ENCALERET; 787583-71-5; EF8081AQ6G; CHEMBL1672973; Encaleret (USAN); ENCALERET [USAN]; 2'-((1R)-1-(((1-(4-chloro-3-fluorophenyl)-2-methylpropan-2-yl)amino)-(2R)-2-hydroxypropoxy)ethyl)-3-methyl(1,1'-biphenyl)-4-carboxylic acid; 2'-((1R)-1-(((2R)-3-((1-(4-chloro-3-fluorophenyl)-2-methylpropan-2-yl)amino)-2-hydroxypropyl)oxy)ethyl)-3-methyl-1,1'-biphenyl-4-carboxylic acid; Encaleret [INN]; (1,1'-Biphenyl)-4-carboxylic acid, 2'-((1R)-1-((2R)-3-((2-(4-chloro-3-fluorophenyl)-1,1-dimethylethyl)amino)-2-hydroxypropoxy)ethyl)-3-methyl-; Encaleret [USAN:INN]; UNII-EF8081AQ6G; ENCALERET [WHO-DD]; CLTX305; SCHEMBL482046; CLTX-305; GTPL9474; BDBM50337103; AKOS040751679; 4-[2-[(1R)-1-[(2R)-3-[[1-(4-chloro-3-fluorophenyl)-2-methylpropan-2-yl]amino]-2-hydroxypropoxy]ethyl]phenyl]-2-methylbenzoic acid; D10068; Q27277151; 2''-((1R)-1-{(2R)-3-[1-(4-Chloro-3-fluorophenyl)-2-methylpropan-2-ylamino]-2-hydroxypropoxy}ethyl)-3-methylbiphenyl-4-carboxylic acid hemisulfate; 2'-((1R)-1-((2R)-3-((1-(4-CHLORO-3-FLUOROPHENYL)-2-METHYLPROPAN-2-YL)AMINO)-2-HYDROXYPROPOXY)ETHYL)-3-METHYL(1,1'-BIPHENYL)-4-CARBOXYLIC ACID
Click to Show/Hide
|
|||
| Drug Type |
Small molecule
|
|||
| Indication | Autosomal dominant hypocalcemia [ICD-11: 5A50.0Y] | Phase 3 | [1] | |
| Company |
Calcilytix Therapeutics
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C29H33ClFNO4
|
|||
| Canonical SMILES |
CC1=C(C=CC(=C1)C2=CC=CC=C2C(C)OCC(CNC(C)(C)CC3=CC(=C(C=C3)Cl)F)O)C(=O)O
|
|||
| InChI |
InChI=1S/C29H33ClFNO4/c1-18-13-21(10-11-23(18)28(34)35)25-8-6-5-7-24(25)19(2)36-17-22(33)16-32-29(3,4)15-20-9-12-26(30)27(31)14-20/h5-14,19,22,32-33H,15-17H2,1-4H3,(H,34,35)/t19-,22-/m1/s1
|
|||
| InChIKey |
UNFHDRVFEQPUEL-DENIHFKCSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Extracellular calcium-sensing receptor (CASR) | Target Info | Antagonist | [2] |
| Pathway Interaction Database | E-cadherin signaling in keratinocytes | |||
| Reactome | G alpha (q) signalling events | |||
| G alpha (i) signalling events | ||||
| Class C/3 (Metabotropic glutamate/pheromone receptors) | ||||
| WikiPathways | GPCRs, Class C Metabotropic glutamate, pheromone | |||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05680818) CALIBRATE: A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With Autosomal Dominant Hypocalcemia Type 1 (ADH1). U.S.National Institutes of Health. | |||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.